The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LSTA1, Lisata Therapeutics’ lead product candidate for the treatment of osteosarcoma, a rare cancer that...

View the Online Magazine

Launches

Getinge and CellRev launch pioneering adherent cell expansion platform

CellRev, in partnership with Getinge, has launched a breakthrough adherent cell expansion platform, Livit ACE. Designed to eliminate many of the limitations and inefficiencies associated...

Data on over 2,300 lung cancer biomarkers mapped in new global database

A new database has been created to support pharmaceutical and biotech companies in the creation of new drugs to treat lung cancer, bringing the...

ACG showcases concept of next generation capsule filling machine – AF330 at CPHI and PMEC 2023

ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is set to unveil its next generation capsule filling...

Suppliers Guide

Check out our Suppliers Guide or contact our team and get your company listed

Subscribe

Keep up with what's happening in the industry and subscribe to our weekly newsletter

Events

Get your event seen by potential candidates on the world's leading industry site.

Supply Chain

Emergent BioSolutions receives $75m contract option from BARDA to procure doses of anthrax vaccine

The Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and...

UK Health Security Agency agrees vaccine deal

The UK Health Security Agency (UKHSA) has agreed a deal for millions of life-saving vaccines to be produced in the UK if a future...

Menarini becomes exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (fixed-dose combination of canagliflozin and metformin) in the UK

A. Menarini Farmaceutica Internazionale SRL (Menarini) has become the exclusive distributor for INVOKANA® (canagliflozin) and VOKANAMET® (a fixed-dose combination of canagliflozin and metformin) in the United...

Outcome Management: The cure for pharma’s toughest trials – by Johannes Müller, co-founder and CEO of Workpath

The pharmaceutical sector is currently grappling with significant challenges that are impacting its operations and long-term viability.  Rising cost pressures due to inflation and...

Approvals

Manufacturiung

Finance

Research & Development
Latest

Lisata Therapeutics gains U.S. FDA Orphan Drug Designation for osteosarcoma treatment

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LSTA1, Lisata Therapeutics’ lead product candidate for the treatment of...

Medicxi and Starpharma create new company to develop novel dendrimer-based treatments

Starpharma has entered into a strategic partnership with Medicxi, a life sciences investment firm dedicated to financing companies developing innovative medicines, to co-found a...

MiNA Therapeutics enters research collaboration with Nippon Shinyaku to develop RNAa therapeutics targeting rare neurodegenerative diseases

MiNA Therapeutics, a pioneer of small activating RNA (RNAa) therapeutics, has announced a research collaboration and licensing agreement option with Nippon Shinyaku, a Japanese-based...

Ipsen and Sutro Biopharma reveal exclusive global licensing agreement for ADC targeting solid tumors

Ipsen and Sutro Biopharma have announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development,...

U.S. FDA Rare Pediatric Disease Designation granted to Lisata Therapeutics’ LSTA1 for the treatment of osteosarcoma

The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to LSTA1, Lisata Therapeutics’ lead product candidate, for the treatment...

Appointments